242-243 / 1676
•
Peak prevalence at different time points (e.g. weekly)
during RT provides most accurate information on acute
side effects
•
Essential information may be lost by using incidence
and/or period prevalence
•
Assessment of baseline “toxicity”
•
Modelling studies on risk factors in general:
•
Include baseline “toxicity” as potential risk factor, OR
•
Exclude patients with baseline “toxicity”
Key points